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Abstract In£uenza A and B viruses are still a major worldwide
threat. We demonstrate that in£uenza B virus infection induces
signaling via the Raf/MEK/ERK cascade, a process required for
e⁄cient virus production. Expression of dominant-negative Raf
and ERK mutants or treatment with a MEK inhibitor (U0126)
strongly impaired viral propagation, while selective activation of
the pathway resulted in increased virus titers. MEK inhibition
appears to interfere with a distinct viral nuclear export process.
Most importantly, no resistant virus variants emerged in the
presence of U0126 demonstrating that in£uenza viruses cannot
easily adapt to the missing cellular function.
/ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
It has long been known that a variety of DNA viruses and
retroviruses induce cellular signaling through the classical mi-
togen-activated protein kinase (MAPK) cascade [1^4]. How-
ever, only little is known about functional signaling via the
Raf/MEK/ERK pathway induced by negative-strand RNA
viruses [5^12].
In£uenza A and B viruses, which represent related but dis-
tinct virus species, are highly contagious worldwide pathogens
for humans. Important characteristics that distinguish in£uen-
za A and B viruses include the restricted host range of type B
viruses to humans, a higher variability and antigenic diversity
of the in£uenza A virus surface proteins and expression of at
least one unique protein by type A or B viruses that has no
obvious counterpart in the other type. Most importantly, in-
£uenza B viruses are not sensitive to the action of amanta-
dine, a compound that e⁄ciently blocks in£uenza A virus
replication [13].
Both viruses possess a negative-strand RNA genome of
eight segments that is replicated and transcribed in the nucleus
of the infected cell. In the late stage of the replication cycle the
viral genome forms ribonucleoprotein complexes (RNPs) that
are exported to the cytoplasm to be packaged into progeny
virions [14^16]. Thus, nuclear RNP export is an essential step
during in£uenza virus replication. Due to the relatively small
coding capacity in£uenza viruses extensively exploit and ma-
nipulate host cell functions to support viral replication [17].
Uncovering these dependencies could help to develop new
strategies for antiviral therapy. We have recently shown that
the Raf/MEK/ERK cascade is activated by type A in£uenza
viruses in a biphasic manner to support viral propagation [8].
Here we investigated whether the related but distinct type B
in£uenza viruses also regulate ERK signaling and whether
such a control is equally required for virus propagation. Fur-
thermore we examined whether resistant variants of in£uenza
A and B viruses will emerge upon inhibition of the Raf/MEK/
ERK signaling cascade.
2. Materials and methods
2.1. Viruses, cells and viral infections
Human in£uenza virus strains B/Lee/40 (B/Lee), B/Maryland/59 (B/
Md), B/Massachusetts/6/93 (B/Mass) and avian in£uenza A/FPV/Bra-
tislava/79 (H7N7) (FPV) viruses were used for infection of Madin^
Darby canine kidney (MDCK) cells that were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) containing 10% heat-inactivated
fetal calf serum (FCS) and antibiotics. Cells were washed with phos-
phate-bu¡ered saline (PBS) and infected at the indicated multiplicity
of infection (MOI) in PBS/BA (PBS containing 0.2% bovine serum
albumin, 1 mM MgCl2, 0.9 mM CaCl2, 100 U/ml penicillin, 0.1 mg/ml
streptomycin) for 1 h at room temperature. The inoculum was aspi-
rated and cells were incubated with DMEM/BA (medium containing
0.2% bovine serum albumin (BSA), antibiotics and 2 Wg/ml trypsin for
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B/Lee, B/Md and B/Mass). The MEK inhibitor U0126 (Promega) in
dimethylsulfoxide (DMSO) or solvent alone were added 30 min prior
to infections and the ¢nal concentrations indicated were kept constant
throughout the experiments. Mitogenic activation of the Raf/MEK/
ERK cascade was achieved by stimulation of cells with 100 ng/ml of
the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA). A
standard plaque assay was used to assess the number of infectious
progeny virus particles (PFU=plaque-forming units).
2.2. Mammalian expression vectors and transfections
The empty expression vector (pKRSPA, empty vector) and plas-
mids expressing dominant-negative mutants of ERK and Raf
(pKRSPA-ERK2B3, pKRSPA-ERK2C3 and pKRSPA-RafC4B)
were described previously [18]. A constitutively active mutant of
Raf (pcDNA-Raf BxB-Cx/DD) was created by fusion of the kinase
domain of c-Raf-1 to the membrane targeting signal of Ki-Ras and by
exchange of two tyrosines at positions 340/341 to aspartic acid to
mimic phosphorylation [19]. A constitutively active mutant of
MEK1 (pBABE vStu1 MEK1 LIDEMANE) was generated by dele-
tion of an autoinhibitory K-helix and by exchange of two activating
phosphorylation sites at positions 218/222 to glutamic acid [18,20].
MDCK cells were transfected with Lipofectamine 2000 (Invitrogen).
2.3. Immune complex kinase assays, in vivo labelling and Western
blotting
Cells were lysed in Triton lysis bu¡er (20 mM Tris^HCl, pH 7.4,
137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 50 mM
Na-glycerolphosphate, 20 mM Na-pyrophosphate, 5 Wg/ml aprotinin,
5 Wg/ml leupeptin, 1 mM Na-vanadate, 5 mM benzamidine) on ice for
10^20 min. Cell lysates were then centrifuged at 13 000Ug for 10 min
at 4‡C and supernatants were used for Western blot analyses and
immune complex kinase assays. To determine the amount of newly
synthesized viral hemagglutinin and nucleoprotein (HA0, NP), blots
from total cell lysates were incubated with a speci¢c antiserum against
in£uenza B virions and a monoclonal antibody (mAb) to NP (DPC
Biermann). Proteins were detected with peroxidase-coupled strepta-
vidin or protein A or G, followed by a standard enhanced chemilu-
minescence reaction (Amersham). To determine activity of the three
MAPKs cell lysates were incubated with antisera to ERK2, c-Jun
NH2-terminal kinase 1 (JNK1) or p38 (Santa Cruz Biotechnology)
and protein A agarose (Roche Molecular Biochemicals) for 2 h at
4‡C. Immune complexes were used for in vitro kinase assays with
puri¢ed myelin basic protein (MBP), glutathione S-transferase-
(GST) fused c-Jun (1^135) or dominant-negative 3pK (3pK KsM)
as substrates for ERK, JNK or p38 as previously described [18].
Proteins were separated by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) and blotted onto polyvinylidene di-
£uoride membranes. Phosphorylated proteins were detected by a BAS
2000 Bio Imaging Analyzer (Fuji) and by autoradiography. Loading
of kinases in the assays was monitored in blots using the respective
anti-kinase antiserum.
2.4. Confocal laser scanning microscopy
MDCK cells grown on glass coverslips were infected (MOI=1),
incubated with media containing solvent (DMSO, 0.6%) or U0126
(60 WM, in DMSO), washed twice with PBS 6 h or 8 h after infection,
¢xed for 20 min with 4% paraformaldehyde, 1% Triton X-100 (in
PBS) at room temperature. After being blocked, ¢xed cells were in-
cubated with NP-speci¢c mAb (1:50, DPC Biermann, Germany) di-
luted in PBS/3% BSA for 1 h. After additional washes cells were
incubated with £uorescein isothiocyanate (FITC)-labelled goat anti-
mouse IgG (1:100, Sigma, Germany) in PBS/3% BSA containing 1 Wg/
ml propidium iodide (PI, Sigma) for 1 h, washed, and mounted with
Mowiol (Aldrich) in glycerol/H2O supplemented with 2.5% DABCO
(Merck). Fluorescence was visualized with a DM IRBE confocal laser
scanning microscope (Leitz).
2.5. Cell viability analysis
MDCK cells were grown to near con£uence in six-well dishes and
either left untreated or incubated with 60 WM U0126 or 0.6% DMSO
for 9 h, 24 h, 48 h or 72 h. After morphological examination cells
were washed twice with PBS, trypsinized, and after two additional
washing steps stained with 1 Wg/ml PI. The proportions of dead and
viable cells were then analyzed in £ow cytometry analysis using a
FACScan (Becton Dickinson).
3. Results
3.1. In£uenza B virus infection results in the activation of the
Raf/MEK/ERK cascade
MDCK cells were infected with three in£uenza B virus
strains (B/Lee, B/Md, B/Mass). At the indicated time points
cell lysates were prepared and subjected to an immune com-
plex kinase assay to analyze ERK activity as a measure for
induction of the Raf/MEK/ERK cascade [8]. Infection of
MDCK cells with B/Lee or B/Md leads to activation of
ERK that steadily increases to reach a plateau around 6 h
post infection (p.i.) (Fig. 1). Essentially the same results were
obtained for B/Mass (data not shown). This indicates that the
activation kinetics induced by in£uenza B viruses di¡ers from
that of in£uenza A viruses that show a biphasic rather than a
linear activation of ERK [8].
3.2. In£uenza B virus-induced Raf/MEK/ERK activity is
critical for viral propagation
To determine the role of virus-induced ERK activity for
in£uenza B virus propagation MDCK cells were infected
with B/Mass at low MOI to allow multi-cycle replication.
The infected cells were incubated for 96 h in the presence or
absence of 60 WM U0126 in DMSO or the solvent alone
(0.6%). To analyze the e⁄cacy of U0126 the inhibitor was
given either once (directly after infection) or twice (directly
and 24 h p.i.) while the other samples received the solvent
DMSO. The production of infectious progeny virions was
determined in supernatants taken every 12 h. After 60 h p.i.
virus titers of U0126-treated cells were reduced by more than
1 log compared to the solvent control (Fig. 2A). Furthermore,
in MDCK cells transfected with plasmids transiently express-
ing dominant-negative forms of ERK and Raf, virus titers
Fig. 1. In£uenza B virus induces ERK activity. MDCK cells were
infected with in£uenza virus B/Lee (A) and B/Md (B) in PBS/BA at
MOI=5. Cells were incubated in DMEM/BA and harvested at the
indicated time points p.i. and ERK2 was immunoprecipitated from
cell lysates as described previously [8]. Immune complexes were sub-
jected to in vitro kinase assay using MBP as a substrate. Proteins
were separated by SDS^PAGE, and labeled substrate bands were
detected by autoradiography. Equal loading of ERK2 proteins was
con¢rmed by Western blot.
FEBS 28112 1-3-04 Cyaan Magenta Geel Zwart
S. Ludwig et al./FEBS Letters 561 (2004) 37^4338
were also reduced about 10-fold (Fig. 2A). In contrast, ex-
pression of constitutively active forms of Raf and MEK led
to increased virus titers. It should be stressed that transfection
e⁄ciencies in these assays were around 60%, thus the e¡ects
are ‘diluted’ by 40% of untransfected wild-type cells. Never-
theless a signi¢cant reduction or enhancement of viral repli-
cation could be achieved, demonstrating a critical role of Raf,
MEK and ERK for in£uenza B virus propagation. The viral
growth curve in the presence of a single dose of U0126 dif-
fered signi¢cantly from the solvent control. In£uenza B virus
titers were already detectable at 36 h p.i. in the control with
increasing titers up to 60 h p.i. Thereafter virus titers declined.
In contrast, in U0126-treated cultures virus growth was se-
verely delayed and was only detectable as late as 60 h p.i.
with reduced peak titers at 84 h p.i. (Fig. 2B). Since the ac-
tivity of the single dose of inhibitor declined gradually in cell
culture and was only barely detectable 24 h p.i. and later (Fig.
2C), recovery of virus growth correlated well with the decrease
in MEK inhibition. This becomes evident when U0126 was
applied twice resulting in a titer reduction of more than 10-
fold throughout the full time course of the experiment (Fig.
2B). In conclusion, inhibition of ERK signaling not only de-
layed virus growth, but also resulted in a reduced peak activ-
ity, even with a ‘one-shot’ treatment.
3.3. MEK inhibition by U0126 is not toxic for MDCK cells
Neither U0126 nor the solvent DMSO was toxic for the
host cells in the concentrations used (Fig. 2D) as determined
by PI staining and £ow cytometry analysis of MDCK cells.
Furthermore, the inhibitor had no adverse e¡ect on vesicular
stomatitis virus (Rhabdoviridae) propagation indicating that
cells remain principally viable and permissive for virus repli-
cation (data not shown). This has also been con¢rmed for
U0126 concentrations that e¡ectively act against Borna dis-
ease virus (Bornaviridae) in several cell types [9].
3.4. U0126 neither a¡ects production of viral HA and NP nor
reduces activity of other virus-induced MAPK cascades
Next, we investigated whether the accumulation of viral
proteins was a¡ected by U0126, thereby leading to a reduc-
tion of progeny virions. The accumulation of both an early
viral protein, the nucleocapsid protein (NP), and a late viral
protein, the hemagglutinin (in the uncleaved form, HA0), was
analyzed. Even though the anti-NP mAb does not detect the
B/Md-NP very well, only slight di¡erences in NP amounts of
U0126- or DMSO-treated cells were detectable (Fig. 3A).
Equally, the amounts of HA0 detected in infected inhibitor-
or solvent-treated cells at 10^14 h p.i. did not di¡er signi¢-
cantly. Partial di¡erences in the protein amounts of HA and
NP may also in part correspond to minor loading di¡erences
as can be seen in the loading control. Taken together these
results indicate that as for in£uenza A viruses [8] the decrease
in virus titers by MEK inhibition cannot be attributed to
severe e¡ects on the viral protein production.
In£uenza A virus infection results in activation of JNK and
p38 MAPK [11,21]. Therefore we analyzed whether type B
Fig. 2. Blockade of Raf signaling impairs in£uenza B virus propagation. A: MDCK cells grown in DMEM, 10% FCS and antibiotics were ei-
ther infected with B/Mass at MOI=1 and incubated for 60 h in DMEM/BA in the presence of U0126 (60 WM) or the solvent DMSO (0.6%)
or were ¢rst transfected with plasmids expressing dominant-negative (dn) forms of ERK (ERK2B3, ERK2C3 (dn ERKB3, dn ERKC3)), or
Raf RafC4B (dn Raf)) as well as constitutively active forms of Raf (pcDNA-Raf BxB-Cx/DD (active Raf)) and MEK (pBABE vStu1 MEK1
LIDEMANE, (active MEK)) or empty vector. Virus titer (PFU/ml) was determined 48 h p.i. by standard plaque assay on MDCK cells shown
as the mean of duplicates titered with di¡erent dilutions. PFU titers of U0126-treated or plasmid-transfected samples were calculated as per-
centage of DMSO- or vector-transfected controls respectively, set at 100%. B: MDCK cells were infected with B/Mass (MOI=0.01) and incu-
bated in the presence of U0126 (applied once p.i. (8) and twice 24 h p.i. (F)) or DMSO (R) (see A) for 96 h. Medium samples collected every
12 h p.i. were analyzed for infectious virions by plaque assay. C: MDCK cells were either left untreated or treated with 60 WM U0126 for the
times indicated. Cells were then stimulated for 15 min with 100 ng/ml of TPA as a strong activator of the Raf/MEK/ERK cascade. Cell lysates
were subjected to ERK2 immune complex kinase assays using MBP as a substrate. Induction of the Raf/MEK/ERK cascade by TPA is e¡ec-
tively inhibited by U0126 up to 9.5 h but increases after 24.5 h of U0126 incubation and is una¡ected after 48.5 h. D: MDCK cells in dupli-
cate were left untreated or were treated with U0126 (60 WM) or the solvent DMSO (0.6%) for 9 h, 24 h, 48 h or 72 h. Cells were stained with
PI (1 Wg/ml) and analyzed by £ow cytometry using FACS analysis. The amount of surviving cells is shown as percentageVS.E.M. of the total
cell number, which was arbitrarily set at 100%.
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virus infection would equally induce activation of these ki-
nases and whether U0126 would in£uence their activity. The
results obtained from immune complex kinase assays of
ERK2, JNK and p38 show that all three kinases are activated
by in£uenza B virus infection, but as compared to virus-acti-
vated ERK, there is no cross-inhibition of JNK or p38 path-
ways by U0126 (Fig. 3B). This demonstrates the speci¢city of
the inhibitor under our experimental conditions.
3.5. MEK inhibition impairs nuclear RNP export
The viral RNPs that are composed of the viral RNA seg-
ments, the NP and the polymerase proteins undergo bidirec-
tional transport across the nuclear membrane during the viral
replication cycle. First, RNPs are transported into the nucleus
where transcription and replication occurs. At a late stage of
the infection cycle, newly formed RNPs are exported to the
cytoplasm and are assembled into progeny virions at the cel-
lular membrane.
Since MEK inhibition a¡ects export of in£uenza A virus
RNPs [8] we investigated the intracellular RNP localization
during in£uenza B virus infection in the presence or absence
of U0126 by immuno£uorescence at di¡erent time points (Fig.
4). NP is the main component of the RNPs and serves as an
indicator for RNP localization [22]. To identify cell nuclei the
cellular DNA was counterstained with PI. The RNPs of
DMSO-treated cells started to appear in the cytoplasm at
6 h p.i. indicating the onset of nuclear export of newly formed
RNPs. In contrast RNPs were still retained in the nucleus of
U0126-treated cells at the same time point. This picture
changed only slightly at 8 h p.i. as only a small fraction of
RNPs was located in the cytoplasm of U0126-treated cells.
These results demonstrate that MEK inhibition negatively af-
fects nuclear export of in£uenza B virus RNPs and implies
that RNP packaging into progeny virions is impaired.
3.6. In£uenza B and A viruses cannot adapt to the selective
pressure of MEK inhibition
The in£uenza virus polymerase does not possess a ‘proof-
reading’ function resulting in a high error rate. This allows the
virus to rapidly adapt to certain selection pressures by muta-
tion, thereby generating resistant variants as shown for the
antiviral agent amantadine [23]. Amantadine has a strain-spe-
ci¢c inhibitory e¡ect on type A but not on type B in£uenza
viruses [24]. The agent blocks the ion channel activity of the
viral M2 protein. It is a common observation that amanta-
dine-sensitive in£uenza A virus strains rapidly develop resis-
tance in vitro and in vivo [23,25^27].
To assess whether continued MEK inhibition may also lead
to the emergence of resistant in£uenza B and A virus variants
we performed multi-passage experiments (Fig. 5). MDCK
cells were infected with B/Mass or FPV [28] at low MOI in
the presence or absence of U0126 (50 WM) or the solvent
Fig. 3. MEK inhibition neither a¡ects viral protein accumulation nor impairs other MAPK cascades. A: MDCK cells were infected with B/Lee
and B/Md at MOI=5 in the presence (+) or absence (3) of U0126 (50 WM) and were lysed at the indicated times p.i. Cell lysates were sub-
jected to SDS^PAGE and blotted on nitrocellulose membranes. Blots were incubated with an antiserum against in£uenza B virions (HA) and
nucleoprotein (NP). Loading of protein in the lysates was monitored with an antiserum against ERK2. B: MDCK cells were infected with
B/Md at MOI=5 in the presence (+) or absence (3) of U0126 (50 WM) and incubated overnight. Cell lysates were subjected to immunoprecipi-
tation with antisera to ERK2, JNK1 or p38. Subsequently immune complex kinase assays were performed as described in Section 2 using puri-
¢ed MBP, GST-c-Jun (1^135) or 3pK KsM as substrates for ERK, JNK or p38 respectively. Loading of the kinases in these assays was
monitored in blots using the respective anti-kinase antibodies.
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(0.5%). The U0126 concentration selected still allowed a low-
level replication giving the residual progeny virus a chance to
adapt to the selective pressure. 48 h p.i. the same amount of
solvent or inhibitor was added again. Supernatant was har-
vested after an additional 24 h and 0.1 ml of a 1032 dilution
was used for the next passage. Five passages were performed
and the virus titer was determined after each passage (Fig.
5A). As a reference, in£uenza A virus (FPV) was passaged
in parallel in the presence of the drug amantadine (5 WM)
and supernatants were harvested 24 h p.i., 0.1 ml of a 1033
dilution was used for the next passage and then proceeded as
described above (Fig. 5B). An initial reduction in B/Mass titer
of 63% with U0126 treatment was enhanced in the following
passages (99%, 96%, 97%, 94%). The virus titer did not rise
again indicating that B/Mass cannot adapt to MEK inhibi-
tion. For the in£uenza A virus FPV the reduction of virus
titers in the presence of U0126 remained constant throughout
all ¢ve passages (82%, 92%, 77%, 95%, 89%) and is in the
range of what was previously reported [8]. Again, emergence
of resistant variants was not observed. In contrast, amanta-
dine treatment resulted in a rapid selection of resistant var-
iants, re£ected by a steady decrease of inhibition (93%, 54%,
38%, 1%, 0%). Even though the initial titer reduction for
B/Mass is not as strong as for FPV the results indicate
that in£uenza A and B viruses do not adapt easily to MEK
inhibition.
4. Discussion
In£uenza A and B viruses are responsible for millions of
infections and thousands of deaths in the human population
worldwide each year. Therefore new information about their
replication strategies could support new approaches in the
¢ght against these foes.
Here we demonstrated that in£uenza B virus infection leads
to a time-dependent increase of cellular ERK activity. Virus
propagation is strongly dependent on the activity of the Raf/
MEK/ERK signaling cascade since not only U0126 treatment
but also expression of dominant-negative forms of Raf and
ERK repressed virus propagation by at least 1 log step (Fig.
2A). Accordingly, constitutively active Raf and MEK sup-
ported an increase in virus titers (Fig. 2A).
Fig. 4. Intracellular localization of viral RNPs. MDCK cells were infected with B/Mass (MOI=1) and incubated with media containing U0126
(50 WM) or the solvent DMSO (0.5%). At the indicated time points (6, 8 h p.i.) cells were ¢xed, permeabilized and incubated with an anti-in£u-
enza B virus NP mAb and subsequently with a FITC-coupled anti-mouse Ab and PI. The intracellular distribution of the viral RNPs and the
cellular DNA was determined by confocal laser scanning microscopy. Cytoplasmic localization of viral RNPs (NP, green) and of selected nuclei
(PI, red) is indicated (white arrows). The merger shows that the intracellular DNA and the RNPs co-localize within the nucleus.
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The antiviral activity of the MEK inhibitor appears to cor-
relate with its stability. At early time points when U0126 ex-
erted its full activity virus production was e⁄ciently sup-
pressed (Fig. 2B) by a single inhibitor dose. Decline of
U0126 activity in cell culture that was obvious 24 h post
treatment and later (Fig. 2C) allowed the residual virus to
further replicate. However, a delay in growth and a reduction
in peak titers was still achieved. Recovery from MEK inhibi-
tion also demonstrated that the U0126 concentrations were
not irreversibly toxic for the cell. This was independently con-
¢rmed as the viability of MDCK cells treated with U0126 was
una¡ected (Fig. 2D). A second dose of U0126 24 h p.i. led to
more than 1 log reduction of the virus titer which persisted up
to 96 h p.i. (Fig. 2B) demonstrating that MEK inhibition
indeed impairs and does not just delay virus replication.
Thus, as long as a MEK inhibitor is biologically active in
cells an e⁄cient reduction of in£uenza B virus replication
could be achieved. The accumulation of viral HA and NP
only showed very small di¡erences in solvent- or U0126-
treated cells (Fig. 3A) indicating that the signi¢cant reduction
of virus titers does not result from altered expression of viral
proteins. This is consistent with earlier studies using in£uenza
A viruses [8].
Previously it was shown that in£uenza A virus infection
activates the JNK and p38 MAPK pathways [11,21]. Here
we demonstrate that in£uenza B virus infection likewise acti-
vates these MAPK cascades (Fig. 3B) in a U0126-una¡ected
manner. This lack of cross-inhibition and the results obtained
with dominant-negative kinases indicate that U0126 exerts its
e¡ect on virus replication speci¢cally through MEK inhibi-
tion.
As observed for in£uenza A viruses [8] U0126 treatment
leads to impaired nuclear RNP export at late stages of the
viral replication cycle (6^8 h p.i.) and even for prolonged
times (10 h p.i., data not shown). Thus both virus types rely
on virus-induced MEK activity for e⁄cient nuclear export of
their RNPs. The molecular mechanism by which ERK activity
regulates RNP export is not clear at the moment. However,
there is ¢rst evidence of distinct ERK-controlled export path-
ways. In lipopolysaccharide (LPS)-treated mouse macro-
phages MEK inhibition results in a speci¢c retention of the
tumor necrosis factor (TNF) mRNA in the nucleus [29]. This
is also observed in cells de¢cient for Tpl-2, an activator of
MEK and ERK. In these cells the failure to activate MEK
and ERK by LPS again correlated with TNF mRNA reten-
tion while other cytokines are normally expressed [29]. Thus
the ERK pathway may regulate a speci¢c cellular export pro-
cess presumably by regulating factors binding to the speci¢c
AU-rich regions in certain mRNAs [29] but leaves other ex-
port mechanisms una¡ected. It is likely that such a speci¢c
export pathway is employed by in£uenza A and B viruses.
Although activated upon in£uenza B virus infection, other
MAPKs such as p38 appear not to be involved in control
of such a pathway. When the p38-speci¢c inhibitor
SB203580 was used, the nuclear export of viral RNPs re-
mained una¡ected (data not shown), indicating that the vi-
rus-induced p38 signaling is not required for RNP export.
This may also explain why U0126, in contrast to other
more general export blockers such as leptomycin B that e⁄-
ciently blocks in£uenza A [30,31] and B virus RNP export
(data not shown), is not toxic for cells. How ERK signaling
controls RNP export is not understood yet and is under in-
vestigation. It could well be directly by phosphorylation of a
viral protein involved in the RNP export process as for exam-
ple the M1 [32,33] or by regulating a cellular factor as men-
tioned above.
The obvious antiviral activity of MEK inhibitors and the
fact that inhibition of the cascade does not severely a¡ect cell
viability ([8,9] and Fig. 2D) suggest that the signaling pathway
may serve as a new target for an antiviral approach. Another
prerequisite for a potent anti-in£uenza compound would be
that the drug does not induce resistant variants, which usually
occurs rapidly with in£uenza A viruses. Therefore we inves-
tigated whether repeated passaging of in£uenza type A and B
viruses in the presence of the drug would lead to emergence of
resistant mutants. In contrast to amantadine, a compound
targeting a viral protein of some in£uenza A type viruses,
U0126 shows no tendency to generate escape mutants of
both A- and B-type in£uenza viruses (Fig. 5). Although this
outcome could not be predicted for a new inhibitor, it is
consistent with an earlier study reporting failure to obtain
Fig. 5. U0126 treatment does not select for resistant in£uenza virus
variants. A: MDCK cells were infected with B/Mass (MOI=0.01)
and incubated 48 h with media and the solvent DMSO (0.5%, black
bars) or U0126 (50 WM, gray bars). The same amount of inhibitor
and solvent was added to the media again and cells were incubated
another 24 h. Diluted supernatant was used for a second round of
infection of fresh MDCK cells. Five passages (1st, 2nd, 3rd, 4th,
5th round) were performed and after each the virus titer (PFU/ml)
was determined by plaque assay. PFU titers of U126-treated sam-
ples were calculated as percentage of DMSO controls set at 100%.
Shown is the mean of duplicate experiments titered in di¡erent dilu-
tions. B: MDCK cells were infected with FPV (MOI=0.01) and in-
cubated 24 h with media containing the solvent DMSO (0.5%, black
bars), amantadine (5 WM, hatched bars) or U0126 (50 WM, gray
bars). Diluted supernatant was used for a second round of infection
of fresh MDCK cells. Five passages (1st, 2nd, 3rd, 4th, 5th round)
were performed and after each the virus titer (PFU/ml) was deter-
mined by plaque assay. PFU titers of amantadine- and U0126-
treated samples were calculated as percentage of DMSO controls set
at 100%. Shown is the mean of duplicate experiments titered in dif-
ferent dilutions.
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drug-resistant in£uenza virus mutants to inhibitors of cellular
factors, such as methyltransferase inhibitors or a broad-band
kinase inhibitor (H7) [27]. Thus, the virus cannot easily adapt
to a missing cellular function. Therefore, transient blockade of
the MAPK cascade, a cellular pathway that supports in£uen-
za A and B virus propagation, may be a novel strategy for
antiviral control of these pathogens.
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